Back

BW-00112 targeting ANGPTL3 results in prolonged reductions in plasma triglycerides, LDL-C, and remnant-C in Chinese healthy subjects

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Drug therapy (1) Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Yuqiong Li

Shanghai (China)

7 More presentations in this session

Presentation thumbnail
The association between the response of lipid-lowering agents and monogenic variants of familiar hypercholesteremia in Taiwan
Professor P. Liu (Tainan, TW)
Abstract Slides Video
Presentation thumbnail
Prospective validation of a self-report-based model for coronary artery calcium screening and assessment of treatment gaps in lipid-lowering therapy.
Doctor E. Hagberg (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM
Professor M. Miller (Philadelphia, US)
Abstract Slides Video
Presentation thumbnail
PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease
Doctor A. Bosch (Erlangen, DE)
Abstract Slides Video
Presentation thumbnail
Effectiveness of statins for primary prevention in the elderly - a propensity score matched cohort study
Doctor D. Leibowitz (Jerusalem, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
LRP3 (low-density lipoprotein receptor-related protein 3), potential metabolic-inflammatory dual regulatory targets of atherosclerosis
thumbnail
Congress Presentation
Phase 1 trial of a monoclonal antibody targeting the angiopoietin-like protein 3/8 complex in patients with mixed hyperlipidaemia
thumbnail
Congress Presentation
Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources